ONL Therapeutics Funding & Investors
Ann Arbor, MI
ONL Therapeutics, Inc. operates as a biopharmaceutical company. The Company develops drugs for the treatment of serious, vision-threatening retinal diseases, and conditions including retinal detachment and wet and dry forms of age-related macular degeneration. ONL Therapeutics serves patients in the United States.
onltherapeutics.comTotal Amount Raised: $147,937,920
ONL Therapeutics Funding Rounds
Series D
$65,000,000
Series D Investors
Johnson & Johnson Innovation – JJDCBios PartnersNovartis Venture FundVisionary VenturesSeries Unknown
$9,999,948
Series C
$15,000,000
Series C Investors
Alpine VisionaryBios PartnersMayewell CapitalVisionary Venture FundExSight VenturesPSQ CapitalBiosciences Research and Commercialization CenterMichigan Capital NetworkKaitai CapitalCapital Community Angel InvestorsJohnson InnovationMINTSSeries B
$46,900,000
Series B Investors
Bios PartnersJohnson & Johnson Innovation – JJDCExSight VenturesCapital Community Angel InvestorsBiosciences Research and Commercialization CenterKaitai CapitalGrand AngelsMINTSInFocus Capital PartnersPSQ CapitalConvertible Note
$3,000,000
Convertible Note Investors
Invest MichiganCapital Community Angel InvestorsInFocus Capital PartnersSeries A
$4,250,000
Series A Investors
NovartisCapital Community Angel InvestorsInvestMichiganBiosciences Research and Commercialization CenterMINTSHestia InvestmentsExSight VenturesGrant
$1,000,000
Grant Investors
National Institutes of Health (NIH)Debt Financing
$916,161
Grant
$1,370,000
Seed
$501,810
Seed Investors
Capital Community Angel Investors
Funding info provided by Diffbot.